RUNX2 and CD4+/CD56+ hematodermic neoplasm: The deletion of the mutant-allele super-enhancer of RUNX2 significantly reduced the expression of MYC and impaired the proliferative capacity of BPDCN cells, indicating that the pDC-specific RUNX2 super-enhancer activates the transcription of MYC. In addition, we investigated how MYC and RUNX2 promote the transformation of BPDCN in mice lacking Tet2 and Tp53.